General Information of Drug (ID: DMJA3H1)

Drug Name
Anti-CEA-CAR T Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1 [1]
Gastric adenocarcinoma 2B72 Phase 1 [1]
Lung cancer 2C25.0 Phase 1 [1]
Pancreatic cancer 2C10 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJA3H1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN CAR-T-Cell-Therapy [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 5.812 11.49 6.112 6.957
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 4.49E-01 -2.02E-03 -0.08
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 2.23E-05 -0.56 -2.16
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer